Navigation Links
Activity Against MRSA is the Most Important Attribute Influencing Physicians' Antibiotic Selection for the Treatment of Skin and Skin Structure Infections
Date:11/4/2008

Success of Zyvox and Cubicin is Driven Strongly by Agents' Excellent Activity Against MRSA, According to a New Report from AMR and Decision Resources

MALVERN, Pa. and WALTHAM, Mass., Nov. 4 /PRNewswire/ --Arlington Medical Resources (AMR) and Decision Resources find that with the rising incidence of skin infections caused by methicillin-resistant Staphylococcus aureus (MRSA), an overwhelming majority of surveyed physicians indicate that the most important attribute influencing antibiotic selection in skin and skin structure infections (SSSIs) is activity against MRSA. Other factors that influence drug selection include an agent's skin penetration and its ability to avoid the development of resistant pathogens.

"Physicians we surveyed also indicate that the two most important factors that influence hospital prescribing for SSSIs are recommendations from infectious disease consults and the Infectious Diseases Society of America (IDSA) guidelines. Clinicians treating patients with SSSIs look to these specialists and guidelines for direction when managing SSSI patients," stated John Lebbos, M.D., vice president of infectious diseases at Decision Resources.

The new report entitled Hospital Anti-Infectives Insight Series: Skin & Skin Structure Infections also finds that surveyed physicians state that the success of Pfizer's Zyvox and Cubist Pharmaceuticals' Cubicin is driven strongly by these agents' excellent activity against MRSA. Vancomycin remains the most commonly prescribed agent for empiric coverage of MRSA, and its use is largely driven by familiarity and local hospital guidelines. In contrast, surveyed physicians indicate that use of Zyvox and Cubicin is driven by product attributes, namely their excellent activity against MRSA activity.

About Hospital Anti-Infectives Insight Series

AMR and Decision Resources' new Hospital Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. These reports examine the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

2008 Hospital Anti-Infectives Insight Series reports include:

-- Hospital Anti-Infectives Insight Series: Nosocomial Pneumonia

-- Hospital Anti-Infectives Insight Series: Skin & Skin Structure

Infections

-- Hospital Anti-Infectives Insight Series: U.S. Antibiotic Usage Patterns

and Drivers in the ICU Setting

About AMR

AMR (http://www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources

Decision Resources (http://www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Natalia Morales Elizabeth Marshall

Decision Resources Decision Resources, Inc.

781-296-2691 781-296-2563

nmorales@dresources.com emarshall@dresources.com


'/>"/>
SOURCE Arlington Medical Resources; Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Tufts Nelson a leader on Physical Activity Guidelines advisory committee
2. Vigorous activity protects against breast cancer
3. YMCA of the USA Supports New National Physical Activity Guidelines
4. ACSM, AHA Support Federal Physical Activity Guidelines
5. Walking forum report shows need to expand physical activity in schools
6. New way to control protein activity could lead to cancer therapies
7. Social Network For Affordable Health Care Supporters Stimulates A New Level of Interactivity and Dialogue
8. Social Network for Affordable Health Care Supporters Stimulates a New Level of Interactivity and Dialogue
9. Banque Centrale Populaire Consolidates Activity Abroad With New Trade Finance Solutions From Misys
10. Gene Activity May Explain Deadlier Breast Cancers Among Younger Women
11. Seizures in newborns can be detected with small, portable brain activity monitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 29, 2017 , ... ... pharmacist Dr. Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March ... common questions regarding thyroid function. , Dr. Izabella Wentz is a licensed ...
(Date:3/28/2017)... NY (PRWEB) , ... March 28, 2017 , ... ... process management software and services, is proud to announce it has joined the ... professional association representing the interests of chronically ill, disabled, and dying Americans of ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., a leader in the ... Systems), the iSAFE and the iSAFE Plus. These iSAFE products are the most affordable ... the iSAFE and iSAFE Plus offer direct GPS Location and two-way calling with the ...
(Date:3/28/2017)... ... 28, 2017 , ... Usually, the impending arrival of warmer weather means the ... about a double chin, this means more anxiety than elation. The cosmetic dermatology experts ... people, a double chin is undesirable,” Dr. Goldman said, “but it seems doubly so ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TORONTO , March 28, 2017 /PRNewswire/ - StarFish ... medical device development firm, announced today that it has ... -based medical device industrial design and productization organization.  ... throughout North America with easier ... talent spanning the design, engineering, regulatory, and manufacturing process. ...
(Date:3/28/2017)... March 28, 2017  Akcea Therapeutics, a subsidiary of Ionis ... company,s board of directors: ... Gabrieli will serve as chairman of the board of Akcea ... commercial officer of Forest Laboratories. Sandford ... "We are excited to announce this ...
(Date:3/28/2017)... , March 28, 2017 ... to reach USD 8.0 billion by 2025, according to ... increasing incidence of infectious diseases and cancer is expected ... in disease diagnosis over the coming years. In addition, ... of autologous and allogenic stem cell therapy, due to ...
Breaking Medicine Technology: